In fairness, we produce monoclonal abs for new indications - and get them into production - constantly. It's one of the richest fields in pharma right now. And people have been having slow-moving but noticeable success with this sort of approach for flu for a few years now. We may get there.

And when we do, it won't be recognizably related to this article, because the pop-sci writer and his headline editor mangled the description so terribly that it bears only a passing resemblance to what the study actually did.